🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

AtriCure, Inc. ATRC R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.atricure.com

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

READ MORE ›
$27.67
-19.96% 1Y

Market & Price

Market Cap
$1.40B
Current Price
$27.67
High / Low (52W)
$42.41 / $26.28
Beta
1.28

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
79.35
PEG Ratio
10.00
Book Value
$9.71
Price to Book
2.85
P/S
2.54
EV/EBITDA
74.92
Dividend Yield
-

Profitability & Returns

ROCE
-0.75%
ROE
-0.97%
ROA
-0.30%
Profit Margin
-0.83%
Op Margin
0.37%
EPS (Latest Qtr)
$0.00
EPS (TTM)
$-0.10

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
2.97
Current Ratio
4.29
Debt
$74.91M
Total Assets
$654.18M
Current Assets
$322.52M
Working Capital
$241.00M

Ownership

Promoter Holding
3.85%
Chg in Prom Hold
0.01%
FII / Inst Holding
102.37%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$1.33B
Total Revenue (TTM)
$552.16M
EBITDA
$17.75M
Free Cash Flow
$41.06M
Operating Cash Flow
$64.36M
Shares Outstanding
50.64M
Gross Margin
75.61%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
17.40%
Profit 5Y
-63.01%
Revenue (YoY)
14.30%
Earnings (YoY)
-

PROS

  • Compounding revenue at 17.4% over 5 years.
  • Generates positive free cash flow.

CONS

  • Earnings shrank at -63.0% CAGR over 5 years.
  • Trading 34.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ATRC AtriCure, Inc. R2K 27.67 - $1.40B - -0.75% -0.97% 17.40% -63.01%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------42.15M-46.99M51.80M49.94M52.89M53.97M58.91M56.61M61.32M53.23M40.82M54.76M57.73M59.27M71.38M70.46M73.22M74.58M84.53M83.25M93.49M100.92M98.29M108.85M116.27M115.91M-123.62M136.14M134.27M140.50M141.25M
Cost of Revenue -----------------------------------30.99M34.66M32.94M35.16M31.94M
Gross Profit 25.55M25.91M28.82M27.47M28.90M30.01M32.55M30.92M32.68M34.50M38.08M35.95M38.59M39.87M43.89M41.80M44.77M38.88M27.65M40.33M42.44M44.54M54.08M52.23M-55.59M63.52M61.71M69.61M77.08M73.87M81.27M86.84M86.79M-92.63M101.48M101.33M105.34M109.31M
Operating Expenses -----------------------------------98.58M107.67M101.12M102.85M108.78M
Operating Income -10.63M-9.42M-7.74M-6.29M-7.70M-9.64M-6.36M-6.85M-2.13M-9.43M958.00K-6.05M-2.61M-5.32M-3.84M-8.64M-15.33M-15.45M-7.29M-3.99M-17.50M-15.88M-15.08M98.67M--14.15M-13.66M-10.72M-5.78M-4.14M-8.09M-10.92M-7.17M-7.41M--5.95M-6.19M208.00K2.49M526.00K
EBITDA ------------------------------------8.00K732.00K6.55M8.97M7.01M
Interest Expense -----------------------------------1.42M1.49M1.47M1.50M1.34M
Pretax Income ------------------------------------6.51M-5.93M-86.00K2.36M394.00K
Tax Provision -----------------------------------239.00K261.00K181.00K604.00K286.00K
Net Income -10.91M-9.72M-8.21M-6.78M-8.62M-10.18M-6.88M-7.25M-2.58M-10.13M-338.00K-7.24M-3.43M-5.63M-4.10M-9.36M-16.10M-16.41M-8.24M-4.95M-18.56M-16.92M-16.25M97.11M--15.18M-14.84M-12.27M-6.48M-5.12M-9.05M-13.27M-8.01M-7.85M--6.75M-6.19M-267.00K1.76M108.00K
Diluted EPS --------------------0.11--0.38-0.362.11--0.33-0.32-0.27-0.14-0.11-0.20-0.28-0.17-0.17--0.14-0.13-0.010.040.00
R&D Expense -8.56M9.12M8.27M-9.55M8.91M7.97M-9.06M8.65M8.56M-8.18M9.80M10.15M-11.59M10.04M10.58M-11.22M12.20M11.28M-13.63M14.79M15.17M15.33M17.44M20.35M19.84M20.42M20.96M-22.53M29.28M22.89M-24.23M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------155.11M174.72M201.63M230.81M206.53M-330.38M399.25M465.31M534.53M
Cost of Revenue -------------84.44M98.88M117.78M133.75M
Gross Profit 41.78M45.39M47.00M50.01M59.56M75.75M92.88M111.10M126.16M147.12M170.34M149.31M-245.94M300.37M347.52M400.78M
Operating Expenses -------------288.61M327.05M387.54M410.23M
Operating Income -15.51M-3.19M-4.73M-7.20M-10.89M-16.36M-26.72M-31.14M-24.98M-17.13M-33.12M-44.23M--42.67M-26.68M-40.01M-9.45M
EBITDA --------------29.50M-8.11M-18.53M16.25M
Interest Expense -------------4.99M6.92M6.41M5.88M
Pretax Income --------------46.20M-29.85M-43.67M-10.16M
Tax Provision -------------268.00K591.00K1.02M1.28M
Net Income -16.49M-3.79M-5.46M-7.53M-11.46M-16.21M-27.21M-33.34M-26.89M-21.14M-35.19M-48.16M50.20M-46.47M-30.44M-44.70M-
Diluted EPS -----------0.94-1.14--1.02-0.66-0.95-0.24
R&D Expense 11.41M11.53M11.86M12.15M13.44M18.60M25.74M35.82M34.14M34.72M41.23M43.07M48.51M57.34M73.92M96.18M99.21M

Compounded Sales Growth

5 Years:17.40%
1 Year:14.30%

Compounded Profit Growth

5 Years:-63.01%
1 Year:-

Stock Price Performance

1 Year:-19.96%
6 Months:-28.09%
3 Months:-11.48%
1 Month:+1.21%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Jan 2024Dec 2024Dec 2025
Total Assets --33.72M33.86M32.43M111.95M158.40M273.09M276.42M267.70M356.76M557.88M714.54M-585.45M613.93M-609.33M654.18M
Current Assets --------------215.21M266.25M-267.83M322.52M
Cash & Equivalents 11.45M8.90M4.23M9.76M7.75M14.89M28.38M23.76M24.21M21.81M32.23M28.48M41.94M-58.10M84.31M-122.72M167.43M
Inventory --------------45.93M67.90M-75.33M78.49M
Receivables --------------42.69M52.50M-60.34M66.65M
Total Liabilities --16.98M18.24M19.93M39.34M25.87M86.41M107.98M106.54M107.38M310.54M302.14M-128.69M147.76M-148.36M162.24M
Current Liabilities --13.04M10.81M12.21M26.71M25.64M31.59M28.83M31.90M40.22M49.92M49.14M-58.39M74.57M-73.42M81.52M
Long Term Debt --------23.89M24.10M35.57M59.63M53.44M-56.83M60.59M61.00M61.87M61.87M
Total Debt --------------74.55M74.49M-73.72M73.38M
Total Equity 29.12M17.09M16.74M15.62M12.50M72.60M132.54M186.69M168.44M161.17M249.38M247.34M412.39M-456.75M466.17M-460.97M491.94M
Shares Outstanding --------------46.56M47.53M-48.87M49.79M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 419.95K-33.00K-1.99M-1.94M-5.22M--7.84M-15.12M-8.94M-4.17M-15.81M-19.87M--22.14M4.48M12.20M57.33M
Investing Cash Flow -2.17M-3.33M2.72M-2.80M-14.15M--10.50M-12.08M3.76M-85.40M-2.15M-156.20M-44.01M21.82M30.23M-14.55M
Financing Cash Flow -914.01K-1.44M4.85M2.66M26.83M-13.96M27.70M2.76M100.18M14.37M189.39M--7.06M-32.00K-3.60M1.18M
Capital Expenditure -1.36M-1.81M-1.52M-2.98M-2.86M-5.51M-13.45M-7.69M-6.38M-6.21M-12.18M-5.26M--16.88M-42.00M-23.46M-15.05M
Free Cash Flow -940.51K-1.85M-3.51M-4.92M-8.09M--21.29M-22.81M-15.33M-10.38M-27.99M-25.13M--39.02M-37.51M-11.26M42.28M
Net Change in Cash -------------14.81M26.27M38.84M43.96M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------71.6%72.2%73.0%73.8%72.3%-74.4%75.2%74.7%75.0%
Operating Margin % --------20.1%-14.3%-8.5%-14.4%-21.4%--12.9%-6.7%-8.6%-1.8%
Net Margin % --------21.5%-15.4%-10.5%-15.2%-23.3%--14.1%-7.6%-9.6%-
ROE % -96.5%-22.7%-34.9%-60.3%-15.8%-12.2%-14.6%-19.8%-16.7%-8.5%-14.2%-11.7%--10.2%-6.5%-9.7%-
ROCE % --15.4%-20.5%-35.6%-12.8%-12.3%-11.1%-12.6%-10.6%-5.4%-6.5%-6.6%--8.1%-4.9%-7.5%-1.6%

Shareholding Pattern

Insiders
3.85%
Institutions
102.37%
Public Float
106.48%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 7.98% 4.04M $111.86M
2 Wellington Management Group, LLP 6.68% 3.38M $93.60M
3 Alliancebernstein L.P. 6.44% 3.26M $90.17M
4 Hood River Capital Management LLC 6.16% 3.12M $86.26M
5 Vanguard Portfolio Management LLC 5.34% 2.70M $74.78M
6 Vanguard Capital Management LLC 4.26% 2.16M $59.65M
7 Nomura Asset Management International Inc 3.56% 1.80M $49.94M
8 Goldman Sachs Group Inc 3.29% 1.67M $46.13M
9 Marshall Wace LLP 2.90% 1.47M $40.61M
10 State Street Corporation 2.57% 1.30M $36.03M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ATRC

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks